Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter studyEva Ellebæk, Dirk Schadendorf, Iva Gavrilova et al.|EJC Skin Cancer|2025Cited by 1